Gerresheimer's Path to Solvency Blocked by Unaudited Accounts

Gerresheimer faces a liquidity crunch as delayed 2025 audit halts refinancing and asset sale. The crisis stems from €35M revenue recognition errors and probes into former leaders.

The clock is ticking for Gerresheimer. The German packaging specialist is navigating a perfect storm of accounting irregularities, regulatory probes, and a liquidity crunch, with its immediate future hinging on a single deliverable: the publication of its audited financial statements for 2025. Without them, critical refinancing talks with lenders remain in limbo, a planned asset sale lacks finality, and the company's published financial targets are essentially provisional.

At the heart of the crisis are systematic errors in revenue recognition. Investigations have uncovered so-called "bill-and-hold" agreements, where goods were invoiced but delivered later—a clear violation of IFRS rules. These faulty bookings impacted €35 million in revenue and €24 million in adjusted EBITDA for the 2024 financial year. The scandal has now ensnared the company's former auditor, KPMG. Germany's audit oversight body, APAS, has initiated professional misconduct proceedings against the firm for issuing an unqualified audit opinion on the flawed 2024 accounts shortly after taking over from Deloitte.

Simultaneously, shareholder association DSW is examining damage claims against former CEO Dietmar Siemssen, former CFO Bernd Metzner, and the supervisory board's audit committee. The focus is on valuation questions surrounding intangible assets worth approximately €676 million and technology values within the Advanced Technologies division, with the potential involvement of a litigation financier.

To shore up its balance sheet, management is taking drastic action. Its most profitable unit, the US prescription drug packaging subsidiary Centor, is on the block with Morgan Stanley managing the sale. The business was last valued on the books at €292 million. While a sale would generate urgently needed capital, it would simultaneously strip the group of a key profit driver, further pressuring future earnings.

The company also anticipates non-cash impairment charges of €220 to €240 million for the 2025 financial year. These writedowns relate primarily to technology and development projects at Sensile Medical AG and assets at its Chicago Heights moulded glass plant, which is slated for closure by the end of fiscal 2026 with production shifting to Italy and India.

The absence of an audited report has frozen Gerresheimer's entire reporting calendar. The 2025 annual report, the Q1 2026 statement, and the ordinary annual general meeting have all been postponed. This failure to meet contractual reporting obligations has placed the company in technical default, forcing it into negotiations with creditors for covenant waivers and deadline extensions. The delay also triggered an automatic expulsion from the SDAX index in March.

Despite the turmoil, management has issued guidance for 2026, forecasting revenue of €2.3 to €2.4 billion and an adjusted EBITDA margin of 18 to 19 percent, aiming for a moderately positive free cash flow. These projections, however, are explicitly conditional on successful outcomes from the creditor talks and ongoing investigations by German financial watchdog BaFin.

All roads now lead to June. The completion of the audited annual financial statements is the mandatory foundation for finalizing credit extensions and providing any certainty to the market. The next fixed reporting date on the calendar is the half-year report on July 14, 2026—a date that has become a critical milestone for the company's entire stabilization effort. Until the June deadline is met, Gerresheimer remains in a holding pattern, its recovery stalled by the very documents meant to assure its health.